![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Endosane is focused on preclinical studies to evaluate the brain delivery characteristics of sol-gel technology and whether pharmacologically relevant concentrations of Cannabidiol can be achieved with this technology.
Lead Product(s): Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Endosane Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Under the terms of the consulting agreement, Veristat will provide services to design and develop PreveCeutical COVID-19 Sol-Gel clinical program and write the required protocol.
Lead Product(s): Cannabidiol
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Veristat
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 04, 2020
Details:
The company has identified a promising modified delivery vector ready for possible pre-clinical experiments based on stable siRNA (small interfering ribonucleic acid) incorporation within the delivery vehicle.
Lead Product(s): siRNA
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020